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Background: Both dietary and serum levels of inorganic phosphate (Pi) have been linked to development of
cancer in experimental studies. This is the first population-based study investigating the relation between serum Pi
and risk of cancer in humans.
Methods: From the Swedish Apolipoprotein Mortality Risk (AMORIS) study, we selected all participants (> 20 years
old) with baseline measurements of serum Pi, calcium, alkaline phosphatase, glucose, and creatinine (n = 397,292).
Multivariable Cox proportional hazards regression analyses were used to assess serum Pi in relation to overall cancer
risk. Similar analyses were performed for specific cancer sites.
Results: We found a higher overall cancer risk with increasing Pi levels in men ( HR: 1.02 (95% CI: 1.00-1.04) for
every SD increase in Pi), and a negative association in women (HR: 0.97 (95% CI: 0.96-0.99) for every SD increase in
Pi). Further analyses for specific cancer sites showed a positive link between Pi quartiles and the risk of cancer of
the pancreas, lung, thyroid gland and bone in men, and cancer of the oesophagus, lung, and nonmelanoma skin
cancer in women. Conversely, the risks for developing breast and endometrial cancer as well as other endocrine
cancer in both men and women were lower in those with higher Pi levels.
Conclusions: Abnormal Pi levels are related to development of cancer. Furthermore, the inverse association
between Pi levels and risk of breast, endometrial and other endocrine cancers may indicate the role of hormonal
factors in the relation between Pi metabolism and cancer.
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Dietary patterns are suggested to be an important en-
vironmental risk factor for cancer [1]. Inorganic phos-
phate (Pi) is a dietary constituent well-known for its
role in skeletal mineralization, and normal levels of Pi
are essential to maintain normal cellular function [2].
Recent experimental studies in rodents indicated that
Pi may act as an active regulator of growth rather
than a merely compulsory element in cellular homeo-
stasis. Elevated levels of serum Pi were found to
modify gene expression as well as protein translation
and affect the rate of cell proliferation in vitro [3,4].
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distribution, and reproduction in any mediumin a significantly increased development of lung and
skin cancers, as well as perturbed normal brain
growth in animal studies [5-7], which denoted the po-
tential link between Pi and carcinogenesis in humans.
However, to our knowledge there are no observational
studies describing the association between Pi and can-
cer risk in humans.
Besides being naturally present in raw food includ-
ing meats, fish, eggs, dairy products and vegetables,
Pi is also found as an additive in processed food
such as hamburgers and pizza, and as phosphoric
acid in soda beverages [8]. Mostly, this Pi content
is not listed as an ingredient per se, and it was
reported that this ‘hidden’ Pi content of food with
Pi-containing additives is nearly 70% higher than
in food without additives [9]. In the human body
Pi is known to be mainly regulated by a set ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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calcium homeostasis, i.e. vitamin D and parathyroid
hormone (PTH), and a recently identified Pi-
regulating hormone, fibroblast growth factor 23
(FGF-23). However, intestinal absorption of Pi is effi-
cient and minimally regulated [2,10], so that high Pi
supplementation results in markedly elevated levels
of serum Pi [11,12]. Additionally, abnormal Pi levels
are also a common feature of various metabolic dis-
eases including diabetes and rickets [13,14]. Consid-
ering the emerging experimental evidence linking Pi
and cancer, it is of interest to explore this relation
in an observational population-based setting.
Methods
Study population and data collection
The Swedish Apolipoprotein Mortality Risk (AMORIS)
database has been described in detail elsewhere [15-17].
Briefly, this database is based on the linkage of the Central
Automation Laboratory (CALAB) database (1985–1996) to
various Swedish national registries, including the National
Cancer Register. The CALAB database includes data from
351,487 male and 338,101 female individuals having clinical
laboratory testing as part of a general health check-up or
outpatients referred for laboratory testing. No individuals
were inpatients at the time their blood samples were taken.
This study complied with the Declaration of Helsinki, and
the ethics review board of the Karolinska Institutet ap-
proved the study (diary number: 2010/1047-31/1).
We selected all participants aged 20 or older with
baseline measurements of serum Pi, calcium (mmol/L),
alkaline phosphatase (mmol/L), glucose (mmol/L) and
creatinine (μmol/L) (n = 397,292). All participants were
free from cancer at time of entry and none were diag-
nosed with cancer or died within three months after
study entry. Follow-up time was defined as the time
from measurement until date of cancer diagnosis, emi-
gration, death, or study closing date (31st of December
2002), whichever occurred first. The CALAB database
also contained information on age, season at time of
measurement, and fasting status. Diagnosis of cancer
were obtained from the National Cancer Register and
classified based on the International Classification of
Diseases, seventh revision (ICD-7; codes for specific can-
cer sites are presented in tables). Socioeconomic status
(SES) was taken from the consecutive Swedish censuses
during 1970–1990 and is based on occupational groups
and classifies gainfully employed subjects into manual
workers and non-manual employees, below designated
as blue-collar and white-collar workers [18]. History of
hospitalization for diabetes (ICD-7: 260) and lung dis-
ease (ICD-7: 470–527; mostly include upper and lower
respiratory tract infections and did not include asthma)
was obtained from the National Patient Register.Serum inorganic phosphate was measured via forma-
tion of the phosphomolybdic acid complex (coefficient
of variation ≤4%) [19]. To assess the effect of small
changes in serum Pi levels, we calculated standardized
values of Pi using its standard deviation (SD) as a unit.
Calcium and alkaline phosphatase were measured by
colorimetric method [20,21], while glucose was mea-
sured enzymatically with a glucose-oxidase/peroxidase
method [22]. Serum creatinine was measured with the
Jaffé method (kinetic) [23]. All laboratory examinations
were performed using described methods above with
automated and calibrated instruments in the same
laboratory [24].
Data analysis
Multivariate Cox proportional hazards models were used
to investigate quartiles and standardized values of serum
Pi as a continuous variable in relation to overall incident
cancer. All models were adjusted for age, gender and
SES. We also took into account serum glucose, fasting
status and history of diabetes based on hospital dis-
charge diagnosis since diabetes is known to modify the
risk of cancer and Pi metabolism is abnormal in diabetic
persons [13,25]. The levels of Pi as well as other metabolic
markers potentially related to cancer are also altered in
metabolic bone disease [26-28], so that additional adjust-
ment for alkaline phosphatase, a marker of bone turnover,
was performed. Our database did not have information re-
garding phosphate regulators, i.e. vitamin D, FGF23 and
parathyroid hormone (PTH) [2,29], but we used season
at time of baseline measurement as a proxy for vitamin D
[30]. Kidney function is also a potential confounder as
renal reabsorption of Pi is a major component in main-
taining physiological Pi levels, and kidney disease is a risk
factor of cancer [31,32]. Thus, serum creatinine was used
in the multivariable models. Further adjustment was done
for history of lung disease as a proxy for smoking as the
latter has been strongly linked to an increased risk of re-
spiratory tract infection [33] To assess reverse causation
[34], we performed a sensitivity analysis in which those
with follow-up <3 years were excluded (n = 10,360). Fi-
nally, we conducted sex-stratified analyses of Pi and risk of
specific cancer sites using quartiles and standardized values
of Pi. All analyses were conducted with Statistical Analysis
Systems (SAS) release 9.1.3 (SAS Institute, Cary, NC).
Results
A total of 31,482 persons developed cancer during mean
follow-of 12.75 years. Most measurements were taken as
part of health examinations done at company health
check-ups, so that the majority of the study population
(84%) was gainfully employed (Table 1). The age of the
participants, serum glucose, alkaline phosphatase and
creatinine were higher in the population with cancer






Age (years) - Mean (SD) 44.00 (14.00) 55.71 (11.93)
Sex
Male 193769 (52.97) 16903 (53.69)
Female 172041 (47.03) 14579 (46.31)
SES
White Collar 132733 (36.28) 12064 (38.32)
Blue Collar 174385 (47.67) 14009 (44.50)
Not gainfully employed
or Missing
58692 (16.04) 5409 (17.18)
Fasting status
Fasting 208923 (57.11) 19547 (62.09)
Non-fasting 113613 (31.06) 8153 (25.90)
Missing 43274 (11.83) 3782 (12.01)
Follow-up time (years) - Mean (SD) 13.12 (3.89) 8.39 (4.68)
Pi1 (mmol/L) Mean (SD) 1.06 (0.17) 1.04 (0.16)
Calcium (mmol/L) Mean (SD) 2.39 (0.10) 2.39 (0.10)
Alkaline phosphatase (mmol/)
Mean (SD)
2.64 (0.96) 2.78 (1.02)
Glucose (mmol/L) - Mean (SD) 4.97 (1.29) 5.19 (1.48)
Creatinine (μmol/L) - Mean (SD) 81.70 (15.22) 83.77 (16.76)
Season
Winter 93580 (25.58) 8328 (26.45)
Spring 99572 (27.22) 8747 (27.78)
Summer 55799 (15.25) 4601 (14.61)
Fall 116859 (31.95) 9806 (31.15)
History of diabetes (ICD-7 260) 1905 (0.52) 201 (0.64)
History of lung disease (ICD-7 470–527) 23709 (6.48) 1791 (5.69)
1Pi inorganic phosphate.
ICD-7, International Classification of Diseases, seventh revision.
Table 2 Hazard ratios and 95% confidence intervals for
the risk of overall cancer for quartiles and standardized
values of serum Pi levels





Men and women combined
Standardized Pi (SD = 0.17) 0.97 (0.96 – 0.99) 0.98 (0.96 – 0.99)
Quartiles of Pi (mmol/L)
< 0.95 1.00 (Ref) 1.00 (Ref)
0.95 – 1.05 0.98 (0.96 – 1.02) 1.00 (0.97 – 1.03)
1.05 – 1.16 0.94 (0.91 – 0.97) 0.95 (0.91 – 0.98)
≥ 1.16 0.94 (0.91 – 0.97) 0.95 (0.92 – 0.98)
P-value for trend < 0.0001 < 0.0001
Men2
Standardized Pi (SD = 0.17) 1.02 (1.00 – 1.04) 1.02 (1.00 – 1.04)
Quartiles of Pi (mmol/L)
< 0.92 1.00 (Ref) 1.00 (Ref)
0.92 – 1.03 1.06 (1.02 – 1.10) 1.05 (1.01 – 1.09)
1.03 – 1.14 1.04 (1.00 – 1.08) 1.03 (0.98 – 1.08)
≥ 1.14 1.07 (1.03 – 1.12) 1.06 (1.01 – 1.12)
P-value for trend 0.01 0.05
Women2
Standardized Pi (SD = 0.16) 0.97 (0.96 – 0.99) 0.97 (0.95 – 0.99)
Quartiles of Pi (mmol/L)
< 0.99 1.00 (Ref) 1.00 (Ref)
0.99 – 1.09 0.95 (0.91 – 0.99) 0.98 (0.93 – 1.04)
1.09 – 1.19 0.93 (0.89 – 0.97) 0.93 (0.89 – 0.99)
≥ 1.19 0.91 (0.87 – 0.96) 0.93 (0.88 – 0.98)
P-value for trend < 0.0001 0.001
All models were adjusted for age, sex, SES, fasting status, calcium, alkaline
phosphatase, glucose, creatinine, season, history of diabetes and lung diseases.
1A sensitivity analysis excluding the first three years of follow-up (n = 386,683).
2Not adjusted for sex.
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in the group without cancer, while no marked difference
in calcium levels was noted between the two groups.
Multivariable Cox proportional hazards ratios for
quartiles of Pi showed a lower risk of overall cancer for
those in the 3rd and 4th quartiles of Pi for both men and
women. This pattern of risk was also observed for
women, but in men higher quartiles were associated
with an increased risk of cancer. When we excluded per-
sons with follow-up <3 years, the positive association be-
tween Pi quartiles and overall cancer risk for men
weakened slightly (Table 2). When using standardized Pi
instead of quartiles, there was a negative association with
risk of overall cancer (HR per SD: 0.97 (95% CI: 0.96-
0.99), P-value < 0.0001). Excluding the first three years
of follow-up did not change the results.
When investigating the relation between quartiles of
Pi and risk of different types of cancer in men, we founda statistically significant increase in the risk of pancre-
atic, lung, thyroid, bone and other cancer in those with
higher Pi quartiles (Table 3). Additionally, a higher risk
of developing cancer of the liver and gallbladder was
found in men in the highest Pi quartile (HR: 1.38 (95%
CI: 1.00-1.91) for the fourth quartile of Pi compared to
the first). Using standardized Pi, a positive association
was also observed between increasing standardized Pi
and the risk of non-Hodgkin’s lymphoma in men, but no
linear association was observed using quartiles of Pi.
However, there was an inverse association between Pi
levels and risk of endocrine cancer other than the thy-
roid gland, prostate, and testis (e.g. HR 0.87 (95% CI:
0.76-1.00) per SD increase of Pi, P-value < 0.0001), al-
though the trend over the quartiles was not linear. There
was also a borderline inverse association between stan-
dardized Pi and risk of colorectal cancer, but this was
not confirmed by Pi quartiles. Excluding other endocrine
Table 3 Hazard ratios and 95% confidence intervals for the risk of site-specific cancer for quartiles of serum Pi in men
Cancer site (ICD-7) n cases Quartiles of Pi (mmol/L), HR (95% CI) P-value
for trend
Standardized
Pi, HR (95% CI)< 0.92 0.92 – 1.03 1.03 – 1.14 ≥ 1.
Lip, oral cavity, pharynx (140–149) 135 1.00 (Ref) 1.12 (0.71 – 1.77) 1.15 (0.71 – 1.86) 1.28 (0.77 2.12) 0.31 1.10 (0.93 – 1.30)
Oesophagus (150) 196 1.00 (Ref) 1.23 (0.84 – 1.80) 1.26 (0.84 – 1.89) 1.43 (0.94 2.18) 0.17 1.12 (0.98 – 1.28)
Stomach (151) 400 1.00 (Ref) 1.10 (0.87 – 1.41) 0.80 (0.60 – 1.07) 1.07 (0.80 1.44) 0.49 0.98 (0.88 – 1.09)
Colorectal (153, 154) 1929 1.00 (Ref) 1.06 (0.94 – 1.18) 0.95 (0.84 – 1.08) 0.91 (0.79 1.05) 0.07 0.95 (0.91 – 1.00)
Liver, gallbladder (155) 319 1.00 (Ref) 1.15 (0.86 – 1.54) 1.07 (0.78 – 1.47) 1.38 (1.00 1.91) 0.14 1.09 (0.98 – 1.22)
Pancreas (157) 427 1.00 (Ref) 1.32 (1.03 – 1.71) 1.27 (0.97 – 1.68) 1.41 (1.05 1.88) 0.02 1.11 (1.02 – 1.22)
Larynx (161) 143 1.00 (Ref) 1.13 (0.72 – 1.77) 1.33 (0.84 – 2.10) 1.28 (0.78 2.10) 0.24 1.11 (0.95 – 1.29)
Lung (162) 1396 1.00 (Ref) 1.24 (1.07 – 1.42) 1.22 (1.05 – 1.42) 1.35 (1.15 1.58) 0.002 1.10 (1.04 – 1.15)
Prostate (177) 5075 1.00 (Ref) 1.01 (0.94 – 1.08) 1.02 (0.94 – 1.10) 0.98 (0.90 1.07) 0.72 0.98 (0.95 – 1.01)
Testis (178) 159 1.00 (Ref) 0.98 (0.60 – 1.58) 0.97 (0.60 – 1.57) 1.11 (0.70 1.75) 0.62 1.02 (0.88 – 1.19)
Kidney (180) 525 1.00 (Ref) 1.05 (0.84 – 1.32) 1.14 (0.90 – 1.44) 0.87 (0.66 1.15) 0.49 1.03 (0.94 – 1.13)
Bladder (181) 1181 1.00 (Ref) 0.99 (0.85 – 1.15) 1.04 (0.89 – 1.21) 1.02 (0.86 1.21) 0.76 1.02 (0.96 – 1.08)
Melanoma of skin (190) 765 1.00 (Ref) 1.02 (0.85 – 1.24) 1.08 (0.89 – 1.32) 1.01 (0.89 1.25) 0.66 1.01 (0.94 – 1.09)
Nonmelanoma of skin (191) 772 1.00 (Ref) 0.95 (0.80 – 1.14) 0.90 (0.74 – 1.10) 1.13 (0.91 1.39) 0.46 0.98 (0.91 – 1.06)
Brain/central nervous system (193) 527 1.00 (Ref) 1.03 (0.82 – 1.31) 1.08 (0.84 – 1.37) 1.06 (0.82 1.37) 0.74 1.01 (0.92 – 1.10)
Thyroid gland (194) 69 1.00 (Ref) 0.94 (0.45 – 1.98) 1.76 (0.90 – 3.43) 1.69 (0.85 3.38) 0.04 1.15 (0.93 – 1.41)
Other endocrine organ (195) 215 1.00 (Ref) 0.46 (0.31 – 0.66) 0.44 (0.29 – 0.65) 0.67 (0.47 0.96) 0.03 0.87 (0.76 – 1.00)
Bone (196) 1690 1.00 (Ref) 1.15 (1.02 – 1.31) 1.15 (1.01 – 1.32) 1.25 (1.08 1.10) 0.002 1.06 (1.01 – 1.11)
Soft tissues (197) 126 1.00 (Ref) 1.48 (0.93 – 2.37) 1.13 (0.67 – 1.92) 1.42 (0.83 2.42) 0.32 1.11 (0.95 – 1.30)
Non-Hodgkin’s lymphoma (200, 202) 613 1.00 (Ref) 1.24 (1.00 – 1.52) 1.06 (0.84 – 1.33) 1.22 (0.96 1.55) 0.25 1.08 (1.00 – 1.17)
Hodgkin’s lymphoma (201) 62 1.00 (Ref) 0.98 (0.82 – 1.18) 1.01 (0.99 – 1.02) 1.45 (0.95 2.22) 0.51 0.92 (0.71 – 1.20)
Multiple myeloma (203) 259 1.00 (Ref) 1.31 (0.96 – 1.77) 0.84 (0.57 – 1.21) 1.20 (0.83 1.74) 0.82 1.02 (0.90 – 1.16)
Leukemia (204–207) 398 1.00 (Ref) 0.88 (0.68 – 1.13) 0.79 (0.59 – 1.04) 0.85 (0.63 1.14) 0.12 0.98 (0.89 – 1.09)
Other cancer1 865 1.00 (Ref) 1.15 (0.96 – 1.38) 1.23 (1.02 – 1.49) 1.38 (1.13 1.68) 0.003 1.10 (1.03 – 1.18)
All models were adjusted for age, SES, fasting status, calcium, alkaline phosphatase, glucose, creatinine, season, history of diabetes and lung diseases.
1Other cancer than the separately presented sites.
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overall cancer in men (e.g. HR: 1.10 (95% CI: 1.03-1.18)
per SD increase in Pi, P-value 0.003, results not shown
in tables).
In women, higher Pi quartiles were related with an in-
creased risk of oesophageal, lung, and nonmelanoma
skin cancer (Table 4). The test for trend also showed
a borderline positive association with risk of laryngeal
cancer, but the limited number of cases resulted in low
statistical power. Increased risks of stomach and bone
cancer were also observed for women in higher quartiles
of Pi compared to the first. In contrast, an inverse asso-
ciation was observed between Pi quartiles and risk of
breast, endometrial and other endocrine cancers. Fur-
thermore, there was an increased risk of colorectal can-
cer risk with every SD increase in Pi, although this was
not confirmed with Pi quartiles. When cancer of the
breast, endometrium, and other endocrine organs were
excluded from the analysis, the inverse association be-
tween Pi and overall cancer risk in women disappeared
(e.g. HR: 1.06 (95% CI: 0.98-1.15) for every SD increase
in Pi, P-value 0.13, results not shown in tables).
Discussion
This is the first study evaluating the association between
Pi and risk of cancer in a population-based observational
setting. We found a positive association between serum
Pi and risk of overall cancer in men, but an inverse asso-
ciation for women using data from a large prospective
Swedish cohort study. Higher Pi quartiles in men was re-
lated to pancreatic, lung, thyroid, bone and other can-
cers. In women, a positive trend was observed between
Pi quartiles and risk of oesophageal, lung, and nonmel-
anoma skin cancer, while a negative association was seen
in breast, endometrial, and other endocrine cancer.
The role of Pi in development of cancer has recently
been suggested. Elevated levels of serum Pi were found
to enhance gene expression as well as protein translation
regulating cell proliferation in vitro [3,4]. Furthermore, a
high phosphate diet has been reported to promote co-
lonic cell hyperplasia and hyperproliferation in mice, in-
dicating a role of Pi in carcinogenesis [35]. Elevated Pi
has been suggested to promote development of cancer
via amplifying Akt signaling activities and enhancing cap-
dependent translation, eventually resulting in increased
cell proliferation [6,36]. On the other hand, also mice
treated with low dietary phosphate have been shown to
develop increased tumourigenesis and enhanced activities
of similar signaling pathways [37]. All these pre-clinical
findings suggest that both high and low Pi may influence
carcinogenesis.
The present study demonstrated that lower Pi was re-
lated to an increased risk of overall cancer in women,
while higher Pi levels were linked to increased overallcancer risk in men. These associations remained clear after
excluding first three years of follow-up, thus no reverse
causation was indicated. Reverse causation between Pi and
cancer is plausible since low Pi levels may be caused by in-
creased Pi excretion. The latter is often reported in cancer
patients and is suggested to occur through renal proximal
tubular dysfunction due to administration of cytotoxic
drugs or cancer progression [38]. This was unlikely to be
the case in the current study.
In the current study, higher Pi levels were associated with
an increased risk of male pancreas, lung, thyroid and bone
cancer and female oesophagus, lung, and nomelanoma skin
cancer. The consistent positive association between Pi levels
and lung cancer corroborated prior biological findings link-
ing high dietary Pi to a significantly increased tumor forma-
tion in mouse models of lung cancer [36]. Additionally,
elevated serum Pi levels have also been reported to enhance
the growth and proliferation of nontumourigenic human
bronchial epithelial (NHBE) cells, and this process was
linked to increased activation of PI3K/Akt as well as Raf/
MEK/ERK pathways which play an important role in car-
cinogenesis [4]. Nevertheless, when higher Pi doses were
administered in similar experiments, a steep decrease in
cell growth was observed, indicating the existence of a Pi
threshold beyond normal range over which cytotoxicity oc-
curs. Further investigation is necessary to define the accept-
able range of Pi levels to maintain physiologic control of
cell growth and function.
The observed relation between Pi and nonmelanoma
skin cancer in women is also in line with previous experi-
mental findings. In a study by Camalier and colleagues,
female mouse models of skin tumorigenesis treated with
high dietary Pi showed a 50% increase of tumor formation
upon 7, 12-dimethylbenz[a]anthracene/12-O-tetradecanoly
phorbol-13-acetate (DMBA/TPA) treatment compared to
those treated with low Pi diet [5]. It was suggested that
Pi affects the formation of skin tumours partly through
increased activation of N-ras and its downstream targets
[5]. For cancer of the brain/central nervous system, we
observed no clear association with Pi levels, despite the
reported effects of Pi on brain growth in animal studies.
Jin et al. suggested that high dietary Pi reduces brain cell
proliferation through suppression of cyclin D1 and PCNA,
two marker proteins related to cell cycle [12]. Neverthe-
less, the same authors also reported increased apoptosis
and related disruptions of cell cycle in normal brain cells
of mice treated with low dietary Pi [7]. Both low and high
levels of Pi are thus likely to impede normal proliferation
of brain cells and may also play a role in carcinogenesis.
However there is lack of observational studies linking Pi
and brain cancer. For colorectal cancer, results in women
corroborated the positive link with Pi as shown in experi-
mental findings in mice, but opposing results were found
in men [35].
Table 4 Hazard ratios and 95% confidence intervals for the risk of site-specific cancer for quartiles of serum Pi in women
Cancer site (ICD-7) n cases Quartiles of Pi (mmol/L), HR (95% CI) P-value
for trend
Standardized
Pi, HR (95% CI)< 0.99 0.99 – 1.09 1.09 – 1.19 ≥ 1.19
Lip, oral cavity, pharynx (140–149) 66 1.00 (Ref) 0.62 (0.30 – 1.29) 0.93 (0.48 – 1.81) 1.05 (0.55 – 2.00) 0.67 1.04 (0.80 – 1.35)
Oesophagus (150) 75 1.00 (Ref) 0.57 (0.25 – 1.30) 1.56 (0.81 – 2.99) 1.95 (1.04 – 3.67) 0.004 1.34 (1.10 – 1.65)
Stomach (151) 251 1.00 (Ref) 1.71 (1.18 – 2.47) 1.48 (1.01 – 2.18) 1.52 (1.03 – 2.25) 0.10 1.13 (0.98 – 1.29)
Colorectal (153, 154) 1410 1.00 (Ref) 1.06 (0.91 – 1.23) 1.04 (0.89 – 1.21) 1.11 (0.96 – 1.30) 0.22 1.06 (1.00 – 1.12)
Liver, gallbladder (155) 260 1.00 (Ref) 1.08 (0.75 – 1.55) 1.38 (0.97 – 1.95) 1.26 (0.88 – 1.81) 0.11 1.09 (0.95 – 1.25)
Pancreas (157) 335 1.00 (Ref) 1.08 (0.80 – 1.46) 0.93 (0.67 – 1.28) 1.24 (0.92 – 1.68) 0.28 1.04 (0.93 – 1.18)
Larynx (161) 16 1.00 (Ref) 2.86 (0.30 – 27.58) 7.31 (0.90 – 59.67) 5.72 (0.66 – 49.37) 0.05 1.36 (0.85 – 2.17)
Lung (162) 887 1.00 (Ref) 1.21 (0.98 – 1.48) 1.51 (1.24 – 1.84) 1.66 (1.37 – 2.02) < 0.0001 1.20 (1.12 – 1.29)
Breast (170) 4925 1.00 (Ref) 0.94 (0.87 – 1.01) 0.89 (0.82 – 0.96) 0.81 (0.75 – 0.88) < 0.0001 0.93 (0.90 – 0.96)
Cervix uteri (171) 318 1.00 (Ref) 1.12 (0.82 – 1.53) 1.09 (0.80 – 1.51) 1.12 (0.82 – 1.54) 0.52 1.03 (0.91 – 1.16)
Endometrium (172) 900 1.00 (Ref) 0.83 (0.70 – 0.99) 0.72 (0.60 – 0.87) 0.72 (0.60 – 0.87) 0.0002 0.84 (0.78 – 0.91)
Ovary (175) 637 1.00 (Ref) 1.00 (0.81 – 1.24) 0.97 (0.78 – 1.20) 0.90 (0.72 – 1.13) 0.31 0.98 (0.90 – 1.07)
Other parts of uterus (174, 176) 67 1.00 (Ref) 0.81 (0.39 – 1.71) 1.37 (0.71 – 2.67) 1.15 (0.58 – 2.29) 0.39 1.07 (0.83 – 1.38)
Kidney (180) 262 1.00 (Ref) 1.19 (0.85 – 1.68) 1.24 (0.88 – 1.75) 1.04 (0.72 – 1.49) 0.81 1.02 (0.89 – 1.16)
Bladder (181) 325 1.00 (Ref) 1.05 (0.77 – 1.43) 1.11 (0.82 – 1.52) 1.02 (0.74 – 1.40) 0.79 1.02 (0.91 – 1.16)
Melanoma of skin (190) 532 1.00 (Ref) 1.02 (0.80 – 1.29) 1.09 (0.86 – 1.39) 0.99 (0.77 – 1.27) 0.93 1.05 (0.95 – 1.15)
Nonmelanoma of skin (191) 442 1.00 (Ref) 1.47 (1.12 – 1.94) 1.33 (1.00 – 1.77) 1.53 (1.16 – 2.04) 0.01 1.12 (1.01 – 1.24)
Brain/central nervous system (193) 456 1.00 (Ref) 0.90 (0.70 – 1.17) 1.00 (0.78 – 1.30) 0.95 (0.73 – 1.24) 0.88 1.00 (0.90 – 1.11)
Thyroid gland (194) 121 1.00 (Ref) 0.77 (0.45 – 1.30) 1.14 (0.70 – 1.85) 0.99 (0.60 – 1.63) 0.65 1.06 (0.88 – 1.27)
Other endocrine organ (195) 407 1.00 (Ref) 0.33 (0.25 – 0.43) 0.15 (0.11 – 0.43) 0.19 (0.14 – 0.26) < 0.0001 0.45 (0.41 – 0.51)
Bone (196) 1080 1.00 (Ref) 1.21 (1.02 – 1.44) 1.20 (1.01 – 1.43) 1.19 (1.00 – 1.42) 0.06 1.08 (1.02 – 1.16)
Soft tissues (197) 93 1.00 (Ref) 0.84 (0.48 – 1.47) 0.79 (0.44 – 1.41) 1.02 (0.58 – 1.78) 0.96 1.02 (0.82 – 1.29)
Non-Hodgkin’s lymphoma (200, 202) 419 1.00 (Ref) 0.96 (0.74 – 1.24) 0.95 (0.72 – 1.24) 0.88 (0.67 – 1.16) 0.38 1.00 (0.90 – 1.11)
Hodgkin’s lymphoma (201) 39 1.00 (Ref) 1.23 (0.62 – 2.43) 1.38 (0.70 – 2.75) 0.63 (0.27 – 1.48) 0.94 1.18 (0.86 – 1.62)
Multiple myeloma (203) 140 1.00 (Ref) 1.31 (0.82 – 2.10) 1.26 (0.78 – 2.04) 1.14 (0.69 – 1.88) 0.70 1.02 (0.84 – 1.22)
Leukemia (204–207) 265 1.00 (Ref) 0.74 (0.51 – 1.06) 0.94 (0.67 – 1.32) 1.26 (0.91 – 1.74) 0.07 1.09 (0.95 – 1.24)
Other cancer1 720 1.00 (Ref) 1.14 (0.92 – 1.40) 1.05 (0.84 – 1.30) 1.20 (0.97 – 1.49) 0.17 1.08 (0.99 – 1.17)
All models were adjusted for age, SES, fasting status, calcium, alkaline phosphatase, glucose, creatinine, season, history of diabetes and lung diseases.
1Other cancer than the separately presented sites.
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http://www.biomedcentral.com/1471-2407/13/257We found a clear inverse association between Pi levels
with risks of female breast and endometrial cancers as
well as “other endocrine cancers”, which drove the inverse
relation with overall cancer risk in women. Breast and
endometrial cancers are well-known to be affected by hor-
monal factors, especially estrogen [39,40]. Increased levels
of estrogen are known to negatively regulate circulating
Pi, both directly and via modulation of PTH levels [41].
Therefore, it is possible that the inverse association be-
tween Pi levels and gynecological cancer risk in women
reflects the underlying estrogen levels. Correspondingly, it
is suggested that hormonal and metabolic factors regulat-
ing Pi, i.e. vitamin D, FGF-23 and PTH, are related to can-
cer incidence [42-44], and thus their abnormal levels may
be responsible for the association between Pi and cancer
risks. Finally, the klotho gene encoding the obligate co-
receptor for FGF-23 is also a putative tumour suppressor
gene [45], further implying the link between Pi regulation
and carcinogenesis.
The major strength of this study is the large number
of subjects with baseline measurements of serum Pi, all
measured in the same laboratory. The use of national
registers provided detailed follow-up information on
diagnosis of cancer, time of death, and emigration for all
subjects. The AMORIS population was mainly selected
based on the availability of blood samples from health
check-ups in non-hospitalized individuals. However, this
healthy cohort effect would not affect the internal valid-
ity of the current study and is likely to be minor since it
has been shown that the AMORIS cohort is similar to
the general working population of Stockholm County in
terms of SES and ethnicity [46]. A limitation of this
study is that there was no available data on dietary Pi in-
take or Pi regulators such as FGF23, PTH, and vitamin
D [29]. There was no information on other possible con-
founders such as smoking status and alcohol consump-
tion. History of lung disease was used as a proxy for
smoking, however some confounding effect of smoking
may remain. For the current study we did not have re-
peated measurements of phosphate to assess its fluctua-
tions over time. Nonetheless, as alteration in phosphate
levels is likely to occur in specific conditions, i.e. kidney
disease, ricketts and diabetes, we adjusted the models
for these diseases using serum creatinine, alkaline phos-
phatase, glucose and history of diabetes in order to more
accurately reflect phosphate levels. Furthermore, a single
measurement of phosphate has been used in many pub-
lished studies to measure the relation between phos-
phate metabolism and other diseases [47,48]
Conclusion
Our findings provide novel epidemiological evidence re-
vealing a decreased cancer risk in women with high Pi and
increased risk in men with high Pi. However, women withhigh Pi displayed a higher risk for developing some spe-
cific cancers including oesophageal, lung, and nonmel-
anoma skin cancer. The persistent negative link between
Pi levels and the risk of breast, endometrial and other
endocrine cancers which drove the inverse relation be-
tween Pi and overall cancer risk in women may imply that
Pi rather serves as a proxy for underlying hormonal or
metabolic factors instigating carcinogenesis. Further stud-
ies in this field should take into account these hormonal
and metabolic factors involved in Pi metabolism and also
the role of dietary Pi, while also addressing the impacts of
other cancer-related effect modifiers beyond the coverage
of the current study.
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